Lamellar to conduct multiple Business Development Meetings about its LAMELLASOME™ technology for safe and effective delivery of nucleic-acid based therapeutics at Biotech Showcase in San Francisco
Glasgow, UK – 4 January 2019 - Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, pioneering new approaches for the safe and effective transfer of functional nucleic acids, announces that Dr Alec McLean, CEO; Steven Porteous, Head of Clinical and Regulatory and Dr Lynsey Howard, Head of Pre-clinical Development will be attending Biotech Showcase in San Francisco 7 -9 January 2019. During the event the Lamellar team will conduct multiple business development meetings with potential partners and investors to highlight the potential of its cutting-edge LAMELLASOME™ technology for the delivery of nucleic acid therapeutics (NAT). These meetings will build on the very positive reaction to its LAMELLASOME™ platform, when it was introduced at BIO-Europe 2018 in Copenhagen in November 2018.
Alec McLean, CEO of Lamellar Biomedical, said, “We were very pleased with the reaction from potential partners and investors when we introduced our LAMELLASOME™ platform for the safe and effective delivery of nucleic acid therapeutics at BIO-Europe late last year. We are now looking forward to multiple new and follow up meetings in San Francisco reflecting the explosion in the number of novel nucleic-acid based therapeutics being developed for a broad range of diseases. Two key factors limiting their progress, from preclinical promise to clinical reality, are safe and effective delivery. Based on our work to-date, Lamellar is confident that it is in an unique position to unlock this enormous potential of nucleic acid based therapeutics using itsLAMELLASOME™ technology.”
Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of many of the nucleic acids in development, including mRNAs, siRNAs, miRNAs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.
In October 2018, Lamellar filed a patent detailing that it had demonstrated functional target downregulation by a transfected nucleic acid delivered via its
LAMELLASOME™ technology. Lamellar has also shown that LAMELLASOME™ formulations have been effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells.
Crucially, all transfected cells types have exhibited very high cell viability and maintenance of cell phenotype/function. Lamellar’s LAMELLASOME™ technology is entirely novel and does not utilise viral vectors or cationic or divalent ion-associated liposomal systems.
Lamellar is also developing its own pipeline of nucleic-acid based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Lamellar is currently completing in-vivo models to demonstrate safe and effective pulmonary delivery and transfection of microRNA(s) prior to executing the final proof of concept efficacy study for its Idiopathic Pulmonary Fibrosis microRNA product in Q1 2019. These studies will be designed to show the performance of LAMELLASOME™ IPF-NA product in-vivo as well as to demonstrate the unique capabilities of LAMELLASOME™ nucleic acid transfer technology platform.
The Lamellar team will be available to present the proprietary LAMELLASOME™ technology to any companies attending Biotech Showcase who see enhanced delivery of their novel nucleic-acid based therapeutics as crucial to their future success.
For further information, please contact:
Dr Alec McLean
+44 (0) 1698 748 832
+44 (0) 1698 532 163
Citigate Dewe Rogerson
David Dible/ Pip Batty/Shabnam Bashir
About Lamellar Biomedical
Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The Company’s unique and versatile LAMELLASOME™ platform has been designed for the safe and effective delivery of nucleic acid based therapeutics. Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of mRNAs, siRNAs, miRNAs, DNA plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.
LAMELLASOME formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been successfully used for the in vivo delivery of functional nucleic acids.
Lamellar is developing its own pipeline of nucleic acid based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Founded in 2007, Lamellar is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities.
LAMELLASOME™ technology comprises synthetic lipid vesicles with compositions based on human lamellar bodies/exosomes. LAMELLASOME™ technology represents a considerable advance in safe and effective non-viral transfection and is distinct from cationic and divalent-ion liposomal systems. LAMELLASOME™ monotherapy formulations have an excellent preclinical safety profile, very high NOAEL (taken from inhalation toxicology) and excellent clinical safety profile.
Lamellar has the capability to formulate bespoke LAMELLASOME™ technology formulations for specific nucleic acids and indications using standard equipment and scalable processes that can optimise the delivery of active substances.
Lamellar Biomedical intends to tailor its LAMELLASOME™ technology to safely and effectively deliver nuclei- acid based therapeutics to their target cells in order to optimise their functionality.